Risk of cardiovascular events among patients with HIV treated with atazanavir-containing regimens: a retrospective cohort study

BACKGROUND: A previous cohort study indicated that atazanavir (ATV), a protease inhibitor used for HIV treatment, is not associated with an increased risk of cardiovascular (CV) events. The objective of this study was to compare the risk of CV events among antiretroviral-naïve patients initiating AT...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenblatt, Lisa, Farr, Amanda M., Nkhoma, Ella T., Nelson, James K., Ritchings, Corey, Johnston, Stephen S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028993/
https://www.ncbi.nlm.nih.gov/pubmed/27643691
http://dx.doi.org/10.1186/s12879-016-1827-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028993/
https://www.ncbi.nlm.nih.gov/pubmed/27643691
http://dx.doi.org/10.1186/s12879-016-1827-1

Ejemplares similares